Biopharma gets its groove back as Q1 approval of NMEs grows
It looks as though the biopharmaceutical industry is back on track to make up for its poor return on research investments last year when only 22 new molecular entities (NMEs) received the FDA's green light, the fewest number for five years. In the first quarter of this year, 12 NMEs were approved, outperforming comparable periods since 2013.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST